At the current average wholesale cost of the smaller, commercially available alteplase vial (containing 50 mg), the average cost per milligram of alteplase is $27.50.

Alteplase was prepared (1) at a concentration of 1 mg/ mL and stored as a 1-mL portion in a polypropylene tube at -20°C for six months or (2) as a 2-mL portion in glass borosilicate vials at -70 ...

Alteplase Medication Information. Discover comprehensive details about Alteplase, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or ...

Reperfusion therapy is an evidence-based intervention for ischemic stroke. 1,2 Intravenous alteplase is the internationally approved standard thrombolytic agent for acute ischemic stroke within 4. ...

The study compared IV tenecteplase to alteplase in almost 1,600 individuals with acute ischemic stroke recruited across 22 Canadian stroke centers, with results showing 0.25 mg/kg tenecteplase was ...

Genentech said it will also introduce a new 25mg vial configuration in the coming months to support the approval of TNKase ..

Alteplase(Cathflo Activase) generic is an enzyme (tissue plasminogen activator (tPA)), prescribed for heart attack, stroke, and pulmonary embolism. It helps to break down unwanted blood clots.

SOUTH SAN FRANCISCO, Calif., March 03, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved ...

The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary late ...

At 90 days, the proportion of patients with a modified Rankin Scale (mRS) score of 0 to 1, the primary outcome, was 62% in the tenecteplase group and 58% in the alteplase group (RR 1.07; 95% CI 0.98-1 ...

A recent paper reports that the use of the drug tenecteplase, not yet approved for stroke treatment in the U.S., may lead to slightly better outcomes after a stroke than the commonly used alteplase.

For the new study, researchers compared nearly 9,500 patients who received tenectplase for stroke to more than 70,000 who got alteplase between July 2020 and June 2022.